Quyen D Chu1,2, Meijiao Zhou3, Kaelen L Medeiros3, Prakash Peddi4,5, Xiao Cheng Wu3. 1. Department of Surgery, Louisiana State University Health Sciences Center in Shreveport, Shreveport, Louisiana, LA, U.S.A. 2. Feist-Weiller Cancer Center, Shreveport, LA, U.S.A. 3. School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA, U.S.A. 4. Feist-Weiller Cancer Center, Shreveport, LA, U.S.A. ppeddi@lsuhsc.edu. 5. Department of Medicine, Louisiana State University Health Sciences Center in Shreveport, Shreveport, Louisiana, LA, U.S.A.
Abstract
BACKGROUND: The Cancer and Leukemia Group B (CALGB) 9343 trial demonstrated that adjuvant radiation therapy (RT) can be omitted in women 70 years or older, with small (≤2 cm), negative lymph nodes, estrogen receptor (ER)-positive breast cancer. We examined whether RT usage following the CALGB publication had decreased over time and evaluated sociodemographic and clinical factors associated with RT omission. MATERIALS AND METHODS: From the National Cancer Data Base, we analyzed a cohort of 120,308 women aged 70 years or older with stage I, ER-positive breast cancer who underwent lumpectomy. Patients were classified into two groups based on the time of CALGB 9343 publication: (i) pre-CALGB (up to 2004), and (ii) post-CALGB (2005-2012). Clinicopathological and sociodemographic variables were compared between pre- and post-CALGB groups. Chi-square and multivariable logistic regression were employed, with the omission of adjuvant RT as the primary outcome in the regression analysis. RESULTS: Radiation therapy usage decreased by 4.1% after CALGB publication (on average 71.6% pre-CALGB vs. 67.5% post-CALGB; p<0.0001). Almost one-third of women aged ≥85 years received RT in the post-CALGB group. In a multivariable model, the variables significantly associated with increased odds for omission of RT in the post-CALGB group were: advanced age, African-American, increased great circle distance, therapy under academic research program, residents of East South-Central region, living in a rural population <2,500 not adjacent to a metropolitan area, low income level, Medicaid recipients, high comorbidity index, small tumor, well-differentiated histology, residual tumor, and lack of receipt of chemotherapy and anti-hormonal therapy. CONCLUSION: During the study period, the CALGB trial publication had a minimal impact on the rate of adjuvant RT use among elderly women with small, ER-positive breast cancers. Significant variation in RT usage existed across sociodemographic strata. Copyright
BACKGROUND: The Cancer and Leukemia Group B (CALGB) 9343 trial demonstrated that adjuvant radiation therapy (RT) can be omitted in women 70 years or older, with small (≤2 cm), negative lymph nodes, estrogen receptor (ER)-positive breast cancer. We examined whether RT usage following the CALGB publication had decreased over time and evaluated sociodemographic and clinical factors associated with RT omission. MATERIALS AND METHODS: From the National Cancer Data Base, we analyzed a cohort of 120,308 women aged 70 years or older with stage I, ER-positive breast cancer who underwent lumpectomy. Patients were classified into two groups based on the time of CALGB 9343 publication: (i) pre-CALGB (up to 2004), and (ii) post-CALGB (2005-2012). Clinicopathological and sociodemographic variables were compared between pre- and post-CALGB groups. Chi-square and multivariable logistic regression were employed, with the omission of adjuvant RT as the primary outcome in the regression analysis. RESULTS: Radiation therapy usage decreased by 4.1% after CALGB publication (on average 71.6% pre-CALGB vs. 67.5% post-CALGB; p<0.0001). Almost one-third of women aged ≥85 years received RT in the post-CALGB group. In a multivariable model, the variables significantly associated with increased odds for omission of RT in the post-CALGB group were: advanced age, African-American, increased great circle distance, therapy under academic research program, residents of East South-Central region, living in a rural population <2,500 not adjacent to a metropolitan area, low income level, Medicaid recipients, high comorbidity index, small tumor, well-differentiated histology, residual tumor, and lack of receipt of chemotherapy and anti-hormonal therapy. CONCLUSION: During the study period, the CALGB trial publication had a minimal impact on the rate of adjuvant RT use among elderly women with small, ER-positive breast cancers. Significant variation in RT usage existed across sociodemographic strata. Copyright
Authors: Lauren J Taylor; Jennifer S Steiman; Bethany Anderson; Jessica R Schumacher; Lee G Wilke; Caprice C Greenberg; Heather B Neuman Journal: Breast Cancer Res Treat Date: 2020-03-03 Impact factor: 4.872
Authors: Shayna L Showalter; Max O Meneveau; Jessica Keim-Malpass; T Fabian Camacho; Gabriella Squeo; Roger T Anderson Journal: Ann Surg Oncol Date: 2021-05-12 Impact factor: 4.339
Authors: Tanja Nadine Stueber; Joachim Diessner; Catharina Bartmann; Elena Leinert; Wolfgang Janni; Daniel Herr; Rolf Kreienberg; Achim Woeckel; Manfred Wischnewsky Journal: PLoS One Date: 2020-05-20 Impact factor: 3.240